MedTrace Logo

Chemotherapy in Treating Patients With Recurrent Malignant Glioma

NCT00002986 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2013-02-20

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase I trial to study the effectiveness of topotecan plus carmustine in patients with recurrent primary malignant glioma.

Conditions

Interventions

DRUG

carmustine

DRUG

topotecan hydrochloride

Sponsors & Collaborators

Principal Investigators

  • Henry S. Friedman, MD · Duke Cancer Institute

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-02-28
Primary Completion
2004-05-31
Completion
2004-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002986 on ClinicalTrials.gov